Adamas Pharmaceuticals Inc (ADMS.OQ)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|53||2000||Chairman of the Board, Chief Executive Officer, Co-Founder|
|63||2017||Chief Financial Officer|
|52||2017||Chief Operating Officer|
|53||2016||Senior Vice President - Human Resources|
|42||2017||Principal Accounting Officer|
- BRIEF-Adamas Q4 Loss Per Share $1.27
- BRIEF-Adamas prices offering Of 3 mln shares at $41.50 per share
- BRIEF-Adamas Announces Proposed Public Offering Of Common Stock
- BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients
- BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04